Reliance Genemedix Share Discussion Threads

[anakin54321] 11/2/2004 09:06

RNS this morning states GMX is to list on NASDAQ. Will further facilitate entry to US market.

[anakin54321] 09/2/2004 23:14

A quick glance at the shareprice history will reveal that the market recovery of the last 10 months or so has had no discernable impact on this share. Currently though it does appear to have stabilised at around the 9 pence mark (it rose significantly today on modest volume) which values GMX at around £27m.


Anyone remotely interested should listen to the Wall Street Reporter interview with the CEO a few weeks ago ( www.wallstreetreporter.com/linked/GeneMedix.html ). It offers a really useful background and investment case (particularly in relation to the recent appointment of US Investment Bankers to provide access to the lucrative American market)and leaves you with the conclusion that the next 2 years could be transformational for this company. It could be argued that everything they've done to date has helped to prepare them for 2005/06 and that the historical shareprice is largely irrelevant. The CEO is certainly very bullish and is confident of licensing deals in the "next few months" from the US which will bring valuable cash to the bottom line.


With the fourth quarter results due on the 26th of this month (according to the website) we could well see a gradual increase over the next couple of weeks in anticipation of more corporate developments.If GMX can make inroads into the US market than its potential will be rapidly realised. After all, it will only take a relatively modest share of a market valued in the tens of billions to transform the share price.

All IMHO.

[qazwsx123] 21/11/2003 11:35

Ultrasis (ULT) a potential 10 to 20 bagger short-term imo.

[qazwsx123] 21/4/2003 10:19

If you are interested in biotechs, you may be interested in the expected news from Alizyme (AZM) as follows:

1) May 2003: PIIb results for Renzapride treating c-IBS (514 patients).
2) Mid 2003: first licensing deal for Colal-Pred.
3) Oct 2003: PIIb results for Renzapride treating m-IBS (170 patients).
4) Oct 2003: PIIb results for ATL-962 treating obesity (340 patients).
5) H2 2003: PIIa results for ATL-104 treating mucositis.
6) Q4 2003: further pharmacokinetic/dynamic results for Renzapride (48 patients in USA).
------------------------------------------------------------------------------
7) 2004: licensing deals for Renzapride treating c-IBS & m-IBS.
8) 2004: licensing deal for ATL-962 treating obesity.
9) H2 2004: PIII results for Colal-Pred (active disease and remission trials).
------------------------------------------------------------------------------
10) H1 2005: Colal-Pred on market.

Sales of Colal-Pred treating active ulcerative colitis should exceed £100m pa, as should sales for maintaining remission; generating revenues of approximately £30 million pa for the Company (i.e. 15% royalties on annual sales of approximately £200 million) (Investor's Chronicle suggested 30% royalties, but that may be on the high side).

Sales of Renzapride, ATL-962 and ATL-104, should generate much higher revenues for Alizyme.

Brett Pollard of analysts Seymour Pierce estimates the licensing deals anticipated for Colal-Pred, Renzapride and ATL-962, during 2003/04, could bring in £50 million cash.

[dil] 19/2/2003 11:56

Looking to break out.

[gardenboy] 19/2/2003 10:12

...and the good news to come now?

[maxk] 19/11/2002 08:37

Fron todays Times:
November 19, 2002

Rumour of the day



GeneMedix firmed ¼p at 16¼p amid suggestions that today's third-quarter results could contain details of a licensing deal in Malaysia. The biotech group, which has a dual listing in Singapore, has recently made the first sales of GM-CSF, which stimulates the production of white blood cells and is used in the treatment of cancer.

[m_p_h] 27/9/2002 23:34

marked up a touch today. Someone short closing??

[m.t.glass] 17/9/2002 23:27

Fell 21% last month. Already down another 23% midway through this month. Relentlessly tumbling towards a single-digit price.

[m.t.glass] 17/9/2002 23:26

Fell 21% last month. Already down another 23% midway through this month. Relentlessly tumbling towards a single-digit price.

[m.t.glass] 09/9/2002 07:54

MMs trimming ahead of visible trades again..

[m.t.glass] 09/9/2002 07:53

And again..

[davidgeran] 03/9/2002 10:37

They're running this one to the wire. Will they generate enough income to complete their development process?? Looking a bit unlikely now :(

[m.t.glass] 03/9/2002 09:58

Prices being cut now by all MMs ahead of any visible trades..

[m.t.glass] 03/9/2002 09:57

Prices now being cut by all MMs before any visible trades..

[m.t.glass] 28/8/2002 15:15

First half losses doubled. What a surprise. Cash remaining £9.4m

RNS announcement seems to be missing?

[m.t.glass] 28/8/2002 15:11

First half losses doubled. What a surprise.
£9.4m cash remaining.

RNS announcement seems to be missing?

[dodddy] 16/8/2002 14:56

plopppp!!!!!:)

[dodddy] 16/8/2002 14:55

some big sellers trying to exit, no brain short to 7p

[rdj20] 07/8/2002 16:36

looks like some more sellers today at 17p- a real dearth of buyers as well. I'm still short and expecting further downward action soon!

[m_p_h] 31/7/2002 12:08

another sell??

[dodddy] 30/7/2002 15:26

100k protected sell, a lot of people want out of this stock

[dodddy] 24/7/2002 15:09

>mph roflmao :)
>mtg time to top down methinks :)

[m_p_h] 24/7/2002 15:04

did I mention a 50k sell? ;-)